Evidence map›Paper›PMID 41449406›Full record

ReviewMolecular brain2025

Early autism detection: a review of emerging technologies, biomarkers, and explainable AI approaches.

Rucha Agrawal, Renuka Agrawal

Abstract readReview
In one paragraph

Review in Molecular brain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rucha AgrawalSymbiosis Institute of Technology, Symbiosis International (Deemed University), Pune, India.
Renuka AgrawalSymbiosis Institute of Technology, Symbiosis International (Deemed University), Pune, India. renuka.agrawal@sitpune.edu.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autism Spectrum Disorder (ASD) presents as a complicated neurodevelopmental disorder which leads to social communication challenges and repetitive behavioral patterns. Early identification of ASD is crucial to facilitate early intervention that can make a large positive impact on long-term developmental outcomes. With the advent of artificial intelligence (AI) and data-driven diagnoses, there is increased interest in combining machine learning methods with biological and behavioral signatures to detect early ASD. This review provides an overview of broad classes of biomarkers-behavioral, neuroimaging, genetic, and eye gaze-and their respective methodologies, clinical applications, and diagnostic accuracy. For each of these biomarker domains, the research gap has been identified as existing for instance limited interpretability in neuroimaging models, genomics-related ethical and data accessibility issues, and innovation saturation for behavioral measurement. A comparative analysis highlights eye gaze analysis as a promising but under-explored option, providing a balance of cost-effectiveness, non-invasiveness, and potential for real-time, objective measurement. In addition, the application of Explainable AI (XAI) methodologies across these biomarker fields is discussed in order to meet the pressing need for transparency, clinical confidence, and decision-making support. This review makes a final call for further exploration of eye gaze-based models enriched by XAI methods as a future research direction towards filling the gap between algorithmic innovation and real-world, interpretable diagnostics in the context of ASD research.

Indexed as

Artificial IntelligenceAutism Spectrum DisorderAutistic DisorderBiomarkersEarly DiagnosisHumansNeuroimagingBiomarkersAIASDAutism spectrum disordereXplainable AIHealthcareNeurodevelopmental disorder

Identifiers

PMID41449406
PMCPMC12849144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.